Epeius Biotechnologies Corporation Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma
6/1/2010 11:56:36 AM
More...
|
Epeius Biotechnologies Corporation: Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies
5/25/2010 8:34:24 AM
More...
|
Epeius Biotechnologies Corporation: Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer
5/25/2010 8:01:10 AM
More...
|
Epeius Biotechnologies Corporation Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
5/5/2010 9:05:20 AM
More...
|
Epeius Biotechnologies Corporation Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
3/16/2010 8:59:45 AM
More...
|
Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
2/19/2010 7:52:30 AM
More...
|
Epeius Biotechnologies Corporation: Scientists Rediscover Gene Target for Cancer Therapy Rexin-G Receives High-tech Validation as Strategic Anti-cancer Agent
12/15/2009 12:11:01 PM
More...
|
Epeius Biotechnologies Corporation to Partner at Biotechnology Industry Organization (BIO) Investor Forum Tumor-targeted Rexin-G is Showcased as a Leading Candidate and Investment Opportunity
10/21/2009 8:46:56 AM
More...
|
Epeius Biotechnologies Corporation: Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer
10/14/2009 10:43:01 AM
More...
|
Epeius Biotechnologies Corporation: Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
10/13/2009 8:21:29 AM
More...
|
|